ETF Securities (ASX:CURE) ETF

The ETFS CURE ETF provides investors with exposure to the US biotechnology sub-industry within the health care sector. CURE adopts an equally weighted strategy, which allocates greater exposure to small and mid-cap shares compared to a market capitalisation weighted approach.

CURE ETF review

ASX: CURE share price and fees

ASX ticker code: CURE
Yearly fee (MER): 0.45%
FUM: $54.01 million
Monthly spread: 0.20%

share price:

Oct
2019
Apr
Jul
Oct
2020
Apr
Jul
Oct
2019
Apr
Jul
Oct
2020
Apr
Jul
Oct
2019
Apr
Jul
Oct
2020
Apr
Jul
Oct
2019
Apr
Jul
Oct
2020
Apr
Jul
$25.00
$27.50
$30.00
$32.50
$35.00
$37.50
$40.00
$42.50
$25.00
$27.50
$30.00
$32.50
$35.00
$37.50
$40.00
$42.50
$25.00
$27.50
$30.00
$32.50
$35.00
$37.50
$40.00
$42.50
$25.00
$27.50
$30.00
$32.50
$35.00
$37.50
$40.00
$42.50
Range: 1 mth | 3 mths | 6 mths | 1 yr | 2 yrs | 5 yrs | 10 yrs

ETF share prices are updated using end of day data from the ASX. FUM, fee and spread data is updated monthly, with a delay. Refer to the ETF’s PDS and the ASX website for up-to-date information.

Data Last Updated: July 2021

Fee comparision

0 %
CURE yearly fee (MER)
0 %
Sector average fee (MER)

A Best ETFs No Rating rating is a fund rating our analysts apply to funds, LICs, mFunds, or ETFs that represents a ‘pending’ or ‘not yet researched’ status for the fund/ETF.

Please note, our rating methodology, research cycle, and process are currently being updated and will soon include full analyst ETF notes, reports, interviews, research, and ratings on select Australian ETFs and funds.

Be sure to subscribe to our mailing list or take our free ETF course while you wait for the updated features. If you’re a fund manager looking to get your fund independently rated by our team, please get in contact.

What does the CURE ASX ETF invest in?

The CURE ETF invests in biotechnology stocks trading on major US exchanges. CURE tracks the performance of the S&P Biotechnology Select Industry Index by holding all of the shares that make up the index, closely in proportion to their index weights. These companies are classified as belonging to the GICS biotechnology sub-industry, and must meet certain market capitalisation and liquidity requirements.

What do investors use the CURE ETF for?

CURE could be used by investors to get tactical exposure to a basket of companies within the USA’s biotechnology industry. Most biotech companies are heavily research-focused and their success can often depend on one breakthrough or regulatory approval, making it a speculative industry.

ASX: CURE’s dividend 2021

CURE dividend yield

Last 12m yield: 10.82%

When does CURE pay a dividend?

CURE dividend reinvestment plan (DRP)

Warnings we apply to the CURE ETF

CURE tax domicile

CURE ETF registry

International shares sector data

0 %
Average FUM
$ 0
Average FUM
0 %
Average fee (MER)

How CURE compares:

0 %
1Y return
$ 0
FUM
0 %
Fee (MER)
Sector information is recorded based on the last 12-month returns to July 2021. Refer to the Issuer’s website, speak to your financial adviser and always the fund’s Product Disclosure Statement (PDS) before choosing an ETF for its dividend yield, past returns or fees. Past performance can be a poor indicator of future performance. 

Latest ETF News

ASX: CURE technical analysis

The Best ETFs technical analysis chart pack shows the 12-month share price movements, Stochastic bands and traded volume (for both up and down days). This chart uses end-of-day data, so it’s for illustrative purposes only.

CURE ETF performance

This chart shows the return of CURE shares up to a maximum of one year (12 months). Data in this chart is based on end-of-day pricing and NOT including dividends/distributions. Past performance is not indicative of future performance.

*The warnings on this page are applied by our ETF research team. Please know that these warnings are based on quantitative metrics and our internal methodology. These risks are not exhaustive and therefore they should not be relied upon. Always read the PDS of the function and speak to your financial adviser before acting on this information.

The Best ETF in Australia?

We’ve found the ONE ETF that could rule them all… 

Right now, there are 200+ ETFs on the ASX. Then there are index funds. Hundreds of managed funds. LICs. REITs. And everything in between. Wouldn’t it be nice to make ONE investment and build the strong Core of your portfolio — with just one click? 

Rask’s lead ETF research analyst and investing team have identified our #1 ETF for 2021 and beyond. Our analyst team has put together a full research report and a step-by-step investment guide to buying this ETF. 

Best of all: The report is totally free and will be sent via email

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian-owned.

General Financial Advice warning
The information on this website is general financial advice only. That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms & Conditions and Financial Services Guide before using this website.

© Rask Australia 2020

Join 20,000+ smart investors

Join the Rask Australia mailing and we’ll send you free investment reports, podcasts, expert insights, investing courses, ASX news and lots, lots more. All free. 

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian-owned.

The 

BEST ETF 

in Australia?

We’ve found the ONE ETF that could rule them all… 

Right now, there are 200+ ETFs on the ASX. Then there are index funds. Hundreds of managed funds. LICs. REITs. And everything in between. Wouldn’t it be nice to make ONE investment and build the strong Core of your portfolio — with just one click? 

Rask’s lead ETF research analyst and investing team have identified our #1 ETF for 2021 and beyond. Our analyst team has put together a full research report and a step-by-step investment guide to buying this ETF. 

Best of all: The report is totally free and will be sent via email

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian-owned.

The 

BEST ETF 

in Australia?

We’ve found the ONE ETF that could rule them all… 

Right now, there are 200+ ETFs on the ASX. Then there are index funds. Hundreds of managed funds. LICs. REITs. And everything in between. Wouldn’t it be nice to make ONE investment and build the strong Core of your portfolio — with just one click? 

Rask’s lead ETF research analyst and investing team have identified our #1 ETF for 2021 and beyond. Our analyst team has put together a full research report and a step-by-step investment guide to buying this ETF. 

Best of all: The report is totally free and will be sent via email

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian-owned.

feedback-icon

What can we do better?

Howdy, ASX investor.

I really care about your experience today.

Please, let me know if you have any suggestions we can use to improve our site and help others invest in ETFs. 

Cheers! 

Owen Rask